FCGRT and myasthenia gravis: The first data to directly support anti-FcRn therapy in human MG came through the phase 2 randomized, double-blind, placebo-controlled, multi-center clinical trial investigating efgartigimod in patients with AChR antibody positive generalized MG (27).